Page last updated: 2024-08-26

bismuth and Minimal Disease, Residual

bismuth has been researched along with Minimal Disease, Residual in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Axtman, A; Bäck, T; Fisher, DR; Frayo, S; Gopal, AK; Green, DJ; Hamlin, DK; Kenoyer, AL; Lin, Y; Orgun, N; Pagel, JM; Park, SI; Press, OW; Shenoi, J; Wilbur, DS	1

Other Studies

1 other study(ies) available for bismuth and Minimal Disease, Residual

Article	Year
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood, 2010, Nov-18, Volume: 116, Issue:20 Topics: Animals; Antibodies, Neoplasm; Antigens, CD20; Biotin; Bismuth; Blood Cell Count; Cell Line, Tumor; Humans; Immunoglobulin Variable Region; Kidney; Liver Function Tests; Lymphoma, Non-Hodgkin; Mice; Neoplasm, Residual; Organometallic Compounds; Radioimmunotherapy; Radiometry; Recombinant Fusion Proteins; Survival Analysis; Tissue Distribution; Xenograft Model Antitumor Assays	2010

Article

Year

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.

Blood, 2010, Nov-18, Volume: 116, Issue:20

Topics: Animals; Antibodies, Neoplasm; Antigens, CD20; Biotin; Bismuth; Blood Cell Count; Cell Line, Tumor; Humans; Immunoglobulin Variable Region; Kidney; Liver Function Tests; Lymphoma, Non-Hodgkin; Mice; Neoplasm, Residual; Organometallic Compounds; Radioimmunotherapy; Radiometry; Recombinant Fusion Proteins; Survival Analysis; Tissue Distribution; Xenograft Model Antitumor Assays

2010